Alkermes ALKS Royalty — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alkermes in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alkermes's royalty — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alkermes's royalty — revenue?
- Alkermes (ALKS) reported royalty — revenue of $50.73M in Q1 2026.
- How has Alkermes's royalty — revenue changed year-over-year?
- Alkermes's royalty — revenue increased by 13.5% year-over-year, from $44.69M to $50.73M.
- What is the long-term trend for Alkermes's royalty — revenue?
- Over 4 years (2021 to 2025), Alkermes's royalty — revenue has grown at a -13.4% compound annual growth rate (CAGR), from $436.18M to $245.26M.
- What does royalty — revenue mean?
- This metric represents the gross revenue recognized from royalty-bearing pharmaceutical products, excluding any pass-through taxes. It reflects the income generated from licensing intellectual property to third parties for the commercialization of drug products. This is a primary indicator of the commercial success and market penetration of the company's licensed therapeutic portfolio.